In addition to variants in RET and POLE (possibly from germline) detected both in the primary tumor and the relapsed tumor, two pathogenic variants in the NSD1 gene appeared in the primary tumor in a significant percentage of cells (15%) that were not detected in the relapsed tumor (if present, they should be in less than 5% of the cells) (Table 2). This evidence concerns the gene POLE and neoplasm.